GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

TECH · Jun 30, 2026

BIO-TECHNE Corp. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 3[email protected]

Inspectable configuration

State dimensions

Filing0001104659-26-100322General Corporate

Debt relative to revenue0thOwn-history percentile · N=10

Evidence method

Level · gp.fundamentals.debt_to_revenue

16.46% · OPTIONAL · VALID

Capex intensity30thOwn-history percentile · N=10

Evidence method

Level · gp.fundamentals.capex_revenue_ratio

2.37% · OPTIONAL · VALID

Operating cash generation40thOwn-history percentile · N=10

Evidence method

Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue

24.04% · OPTIONAL · VALID

Revenue growthRAWCurrent state valid · history insufficient

Evidence method

Yoy · gp.fundamentals.revenue

-0.38% · CORE · NOT_ENOUGH_HISTORY

Inventory pressure20thOwn-history percentile · N=10

Evidence method

Level · gp.fundamentals.inventory_revenue_ratio

16.11% · OPTIONAL · VALID

Gross margin60thOwn-history percentile · N=10

Evidence method

Level · gp.fundamentals.gross_margin

65.77% · CORE · VALID

Operating margin80thOwn-history percentile · N=10

Evidence method

Level · gp.fundamentals.operating_margin

20.73% · CORE · VALID

SBC intensity40thOwn-history percentile · N=10

Evidence method

Level · gp.fundamentals.sbc_revenue_ratio

3.40% · OPTIONAL · VALID

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History11 statesHistory building

Dec 31, 20230/7 normalizedLevel 3 Mar 31, 20240/7 normalizedLevel 3 Jun 30, 20240/7 normalizedLevel 3 Sep 30, 20240/7 normalizedLevel 3 Dec 31, 20240/8 normalizedLevel 3 Mar 31, 20250/8 normalizedLevel 3 Jun 30, 20250/8 normalizedLevel 3 Sep 30, 20250/8 normalizedLevel 3 Dec 31, 20257/8 normalizedLevel 3 Mar 31, 20267/8 normalizedLevel 3 Jun 30, 20267/8 normalizedLevel 3

Period transition

What moved in the state?

Balance Sheet Leverage Decreased

Previous: 64.22%
Current: 16.46%
Delta: -47.76%

Capex Intensity Decreased

Previous: 2.92%
Current: 2.37%
Delta: -0.54%

Cash Generation Decreased

Previous: 27.83%
Current: 24.04%
Delta: -3.79%

Growth Increased

Previous: -1.51%
Current: -0.38%
Delta: 1.13%

Inventory Pressure Decreased

Previous: 64.60%
Current: 16.11%
Delta: -48.49%

Margin Decreased

Previous: 66.88%
Current: 65.77%
Delta: -1.12%

Profitability Decreased

Previous: 24.24%
Current: 20.73%
Delta: -3.51%

Sbc Intensity Increased

Previous: 3.37%
Current: 3.40%
Delta: 0.03%

Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Not enough compatible prior states for a transparent self-history match.

Research Graph

Related governed research

Has State · BIO-TECHNE Corp →Transitioned To · TECH Fundamental State →Transitioned To · TECH BALANCE_SHEET_LEVERAGE_DECREASED →Transitioned To · TECH CAPEX_INTENSITY_DECREASED →Transitioned To · TECH CASH_GENERATION_DECREASED →Transitioned To · TECH GROWTH_INCREASED →Transitioned To · TECH INVENTORY_PRESSURE_DECREASED →Transitioned To · TECH MARGIN_DECREASED →Transitioned To · TECH PROFITABILITY_DECREASED →Transitioned To · TECH SBC_INTENSITY_INCREASED →

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.